sodium glucose cotransporter 2 sglt2 inhibitors market, sodium glucose cotransporter 2 sglt2 inhibitors market growth report, sodium glucose cotransporter 2 sglt2 inhibitors market size, sodium glucose cotransporter 2 sglt2 inhibitors market share analysis, north america sodium glucose cotransporter 2 sglt2 inhibitors market, sodium glucose cotransporter 2 sglt2 inhibitors market forecast
What is the current market size and future outlook for the sodium glucose cotransporter 2 (sglt2) inhibitors market?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown strongly in recent years. It will grow from $10.17 billion in 2024 to $11.07 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to early clinical trial successes, rising regulatory approvals, increasing diabetes diagnosis rates, and the demand for innovative diabetes treatments.
The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.
Get Your Free Sample of The Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp
How has the sodium glucose cotransporter 2 (sglt2) inhibitors market evolved, and what factors have shaped its growth?
The increasing prevalence of diabetes is expected to propel the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market going forward. Diabetes refers to a group of metabolic disorders characterized by high blood sugar levels resulting from defects in insulin secretion, insulin action, or both. The rise in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollutants, and a lack of access to healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. They also offer cardiovascular and renal benefits, making them a valuable option for managing diabetes and its complications. For instance, in December 2023, according to Australian Bureau of Statistics, an Australian based government agency, in 2022, 5.3% of Australians, or about 1.3 million people, were diagnosed with diabetes, with rates similar between males (5.8%) and females (4.9%). Diabetes prevalence has been steadily increasing, significantly rising with age, reaching 18.7% among those aged 75 and older. Type 2 diabetes is the most common form, accounting for 87.6% of cases. Factors such as being born overseas, living in disadvantaged areas, and having a disability are associated with higher diabetes rates. Therefore, the increasing prevalence of diabetes is driving the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.
What are the major segments of the sodium glucose cotransporter 2 (sglt2) inhibitors market?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –
1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics
Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure
Order your report now for swift delivery
Which companies dominate the sodium glucose cotransporter 2 (sglt2) inhibitors market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.
How will evolving trends contribute to the growth of the sodium glucose cotransporter 2 (sglt2) inhibitors market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are focused on developing dual inhibitor therapeutic solutions to improve patient outcomes and manage blood sugar levels. Dual inhibitor therapeutic solutions refer to treatments that simultaneously target two different sodium-glucose cotransporters (SGLT1 and SGLT2) to enhance efficacy in managing conditions such as heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet designed to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include reduced renal glucose and sodium reabsorption, which leads to preload and afterload reduction and decreased sympathetic activity.
What are the key regional dynamics of the sodium glucose cotransporter 2 (sglt2) inhibitors market, and which region leads in market share?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2025 Offer?
The sodium glucose cotransporter 2 (sglt2) inhibitors market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
